[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100425599":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":37,"responsibleParty":112,"collaborators":20,"id":116,"slug":117,"hasResults":118,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":118,"sex":124,"minAge":125,"maxAge":20,"enrollmentInfo":126,"targetDuration":20,"studyType":129,"phases":130,"briefSummary":132,"conditions":133,"keywords":137,"overallStatus":40,"whyStopped":20,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},{"fullName":5,"class":6},"Swedish Lung Cancer Study Group","NETWORK",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Proton radiotherapy","EXPERIMENTAL","Proton radiotherapy with RBE doses:\n\n* Patients with radical surgery and unfavourable histology (B2, B3, C) and\u002For Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).\n* Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)\n* Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)",[13],"Radiation: Proton radiation",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Proton radiation","* Patients with radical surgery and unfavourable histology (B2, B3, C) and\u002For Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).\n* Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)\n* Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Hillevi Rylander, MD","Head of Skandion Clinic","STUDY_DIRECTOR",[27,33],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Jan Nyman, Ass.prof.","CONTACT","+46313421000","27927","jan.nyman@oncology.gu.se",{"name":34,"role":29,"phone":35,"phoneExt":20,"email":36},"Andreas Hallqvist, MD, PhD","+46739845114","andreas.hallqvist@vgregion.se",[38,65,85],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Department of Oncology, Norrlands Universitetssjukhus","RECRUITING","Umeå","Norrland","901 85","Sweden","SE",{"type":47,"coordinates":48},"Point",[49,50],20.25972,63.82842,{"lat":50,"lon":49},[53,57,60,62],{"name":54,"role":29,"phone":55,"phoneExt":20,"email":56},"Mikael Johansson, MD PhD","0046703711414","mikael.johansson@onkologi.umu.se",{"name":58,"role":29,"phone":20,"phoneExt":20,"email":59},"Per Bergström, MD PhD","per.bergstrom@vll.se",{"name":54,"role":61,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"name":63,"role":64,"phone":20,"phoneExt":20,"email":20},"Per Bergström, MD","SUB_INVESTIGATOR",{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":44,"countryCode":45,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Department of Oncology, Karolinska University Hospital","NOT_YET_RECRUITING","Stockholm","Stockholm County","171 76",{"type":47,"coordinates":72},[73,74],18.06871,59.32938,{"lat":74,"lon":73},[77,80,83,84],{"name":78,"role":29,"phone":20,"phoneExt":20,"email":79},"Signe Friesland, MD PhD","signe.friesland@sll.se",{"name":81,"role":29,"phone":20,"phoneExt":20,"email":82},"Michael Gubanski, MD PhD","michael.gubanski@sll.se",{"name":78,"role":61,"phone":20,"phoneExt":20,"email":20},{"name":81,"role":64,"phone":20,"phoneExt":20,"email":20},{"facility":86,"status":40,"city":87,"state":88,"zip":89,"country":44,"countryCode":45,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Department of Oncology, Sahlgrenska University Hospital","Gothenburg","Västra Götaland County","413 45",{"type":47,"coordinates":91},[92,93],11.96679,57.70716,{"lat":93,"lon":92},[96,99,100,102,104,105,107,109,111],{"name":97,"role":29,"phone":98,"phoneExt":20,"email":32},"Jan Nyman, Ass prof","0046313427927",{"name":34,"role":29,"phone":35,"phoneExt":20,"email":36},{"name":101,"role":64,"phone":20,"phoneExt":20,"email":20},"Andreas Hallqvist, MD PhD",{"name":103,"role":64,"phone":20,"phoneExt":20,"email":20},"Annica Ravn-Fischer, MD phD",{"name":23,"role":64,"phone":20,"phoneExt":20,"email":20},{"name":106,"role":64,"phone":20,"phoneExt":20,"email":20},"Anna Bäck, PhD",{"name":108,"role":64,"phone":20,"phoneExt":20,"email":20},"Erik Lundin, MD",{"name":110,"role":64,"phone":20,"phoneExt":20,"email":20},"Jens Engleson, MD",{"name":97,"role":61,"phone":20,"phoneExt":20,"email":20},{"type":113,"investigatorFullName":114,"investigatorTitle":115,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Ass. Prof. Jan Nyman","Head of Swedish Lung Cancer Study Group, Ass. Prof.","100425599","study-on-proton-radiotherapy-of-thymic-malignancies-100425599",false,"NCT04822077","Study on Proton Radiotherapy of Thymic Malignancies","PROTHYM - Phase II Non-randomized Study on Proton Radiotherapy Of Thymic Malignancies","PROTHYM","Inclusion Criteria:\n\n* Histological or cytological diagnosis of thymoma or thymic carcinoma.\n* With radical surgery: stage III and IVa and selected stage II with type B2, B3 and thymic carcinoma according to local routine. With non-radical surgery (R1 or R2) or inoperable patient\u002F patient refusing surgery: stage I - IVa, any histology\n* PS WHO 0 - 2.\n* FEV1 \\> 1L or \\>40 % of predicted and CO diffusion capacity \\> 40% of predicted (postoperative measures)\n* Age \\>18 years, no upper age limit.\n* Written informed consent from patients.\n\nExclusion Criteria:\n\n* Masaoka-Koga stage IVb (distant metastases).\n* Pregnancy.\n* Serious concomitant systemic disorder incompatible with the study.\n* Tumour motion \\> 0.5 cm on two repeated 4DCT","ALL","18 Years",{"count":127,"type":128},40,"ESTIMATED","INTERVENTIONAL",[131],"NA","This is a multicentre non-randomized phase II study of proton beam radiotherapy in patients with thymic epithelial tumours (i.e. thymoma and thymic carcinoma) in the post-operative setting or in inoperable patients with localized disease.\n\nPatients not willing or for any reason unsuitable to undergo proton treatment will be asked to participate in a follow-up assessment after the regular photon treatment in the same manner as the included patients.\n\nPrimary endpoints are:Toxicity (e.g. cardiac and pulmonary toxicity) and Local control at 5 year Secondary endpoints: PFS, Overall survival, Quality of life, measured by EORTC QLQ 30 + LC 13 and relapse pattern",[134,135,136],"Cardiotoxicity","Pulmonary Toxicity","Thymus Neoplasms",[138,139,9],"Thymoma","Thymic carcinoma","2021-03-25",{"date":142,"type":143},"2021-03-30","ACTUAL",{"date":145,"type":143},"2018-04-18",{"date":147,"type":128},"2029-04-01",{"name":114,"class":6},3]